Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / CD Molecules

Recombinant Human CD89/FCAR Protein, N-GST

Catalog #:   YHJ95401 Specific References (50) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: E. coli
Accession: P24071
Protein length: Gln22-Asn227
Overview

Catalog No.

YHJ95401

Expression system

E. coli

Species

Homo sapiens (Human)

Protein length

Gln22-Asn227

Predicted molecular weight

50.32 kDa

Nature

Recombinant

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

P24071

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

CD89, Immunoglobulin alpha Fc receptor, FCAR, IgA Fc receptor

Data Image
  • SDS-PAGE
    SDS PAGE for recombinant Human CD89/FCAR protein
References

Enrichment of human IgA-coated bacterial vesicles in ulcerative colitis as a driver of inflammation., PMID:40301356

Targeting ALPPL2 with a novel CD89 bispecific antibody reprograms macrophages to enhance anti-tumor immunity., PMID:40209501

Dapsone Alters Phenotypical and Functional Properties of Human Neutrophils In Vitro., PMID:39795170

In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models., PMID:39735543

Circulating mucosal-like IgA responses increase with severity of Puumala orthohantavirus-caused hemorrhagic fever with renal syndrome., PMID:39512345

The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy., PMID:39358557

Genetic Profile of Beta-Thalassemia and Sickle Cell Disease in Eastern Uttar Pradesh., PMID:39267277

Blood soluble CD89-IgA complex may be a potential biomarker for predicting multi-organ involvement, especially renal involvement in children with immunoglobulin A vasculitis., PMID:39241523

ITPK1 Sensitizes Tumor Cells to IgA-dependent Neutrophil Killing In Vivo., PMID:39213127

FcαRI (CD89) is upregulated on subsets of mucosal and circulating NK cells and regulates IgA-class specific signaling and functions., PMID:38677592

The gut microbiota posttranslationally modifies IgA1 in autoimmune glomerulonephritis., PMID:38536935

Mass Spectrometry-Based Characterization of Protein Aggregates in Tissues and Biofluids., PMID:38409426

Fc receptors are key discriminatory markers of granulocytes subsets in people living with HIV-1., PMID:38384451

SIgA structures bound to Streptococcus pyogenes M4 and human CD89 provide insights into host-pathogen interactions., PMID:37872175

The Structures of Secretory IgA in complex with Streptococcus pyogenes M4 and human CD89 provide insights on mucosal host-pathogen interactions., PMID:37662389

DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection., PMID:37639455

The role of mononuclear phagocyte system in IgA nephropathy: pathogenesis and prognosis., PMID:37529043

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models., PMID:37479484

Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains., PMID:37338671

Proteomic analysis of circulating immune cells identifies cellular phenotypes associated with COVID-19 severity., PMID:37302069

Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350/CD89-targeted bispecific antibody., PMID:37126928

Antagonizing FcαR1 (CD89) as treatment in IgA-mediated chronic inflammation and autoimmunity., PMID:37081893

Current Status and Perspectives on Recurrent IgA Nephropathy after Kidney Transplantation., PMID:36966530

Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA., PMID:36817447

Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade., PMID:36460336

Fcα Receptor-1-Activated Monocytes Promote B Lymphocyte Migration and IgA Isotype Switching., PMID:36232432

Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer., PMID:35854649

Anti-FcαRI Monoclonal Antibodies Resolve IgA Autoantibody-Mediated Disease., PMID:35371001

Specific immune biomarker monitoring in two children with severe IgA nephropathy and successful therapy with immunoadsorption in a rapidly progressive case., PMID:34997322

Therapeutic exploitation of neutrophils to fight cancer., PMID:34922817

Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy., PMID:34756952

Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma., PMID:34716207

Fecal Microbiota Transplantation Modulates Renal Phenotype in the Humanized Mouse Model of IgA Nephropathy., PMID:34712223

Poly-IgA Complexes and Disease Severity in IgA Nephropathy., PMID:34607844

IgA Immune Complexes Induce Osteoclast-Mediated Bone Resorption., PMID:34276648

Are there animal models of IgA nephropathy?, PMID:34230994

IgA vasculitis., PMID:34170395

Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice Model., PMID:33923466

IgA and FcαRI: Versatile Players in Homeostasis, Infection, and Autoimmunity., PMID:33447585

Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials., PMID:33197478

Mucosal Therapy of Multi-Drug Resistant Tuberculosis With IgA and Interferon-γ., PMID:33193394

Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41., PMID:32582208

Establishment of human iPSC line from patient of Indian ethnicity carrying homozygous CD8/9 (+G) beta thalassemia mutation., PMID:32278313

Food antigens and Transglutaminase 2 in IgA nephropathy: Molecular links between gut and kidney., PMID:32135400

Immunological Pattern in IgA Nephropathy., PMID:32085673

Serum Soluble CD89-IgA Complexes Are Elevated in IgA Nephropathy without Immunosuppressant History., PMID:32076466

High-Content Immunophenotyping and Hierarchical Clustering Reveal Sources of Heterogeneity and New Surface Markers of Human Blood Monocyte Subsets., PMID:31887780

Serum IgA Fc effector functions in infectious disease and cancer., PMID:31785006

Single-Cell Analysis of Human Mononuclear Phagocytes Reveals Subset-Defining Markers and Identifies Circulating Inflammatory Dendritic Cells., PMID:31474513

Shine & Lal index as a predictor for early detection of β-thalassemia carriers in a limited resource area in Bandung, Indonesia., PMID:31399060

Datasheet
$ 313
Product specifications
100 μg 313 1 mg 1629

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant Human CD89/FCAR Protein, N-GST [YHJ95401]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only